SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-002405
Filing Date
2023-01-05
Accepted
2023-01-05 16:16:00
Documents
12
Period of Report
2023-01-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d436852d8k.htm   iXBRL 8-K 22912
  Complete submission text file 0001193125-23-002405.txt   140556

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20230104.xsd EX-101.SCH 2868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20230104_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20230104_pre.xml EX-101.PRE 10824
6 EXTRACTED XBRL INSTANCE DOCUMENT d436852d8k_htm.xml XML 3240
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 23511494
SIC: 2834 Pharmaceutical Preparations